Cure SMA Welcomes Broad FDA Approval of Itvisma™ for Spinal Muscular Atrophy, Reinforces Commitment to Patient Access and Support
Cure SMA, the leading nonprofit organization dedicated to supporting those impacted by spinal muscular atrophy (SMA), welcomes the FDA approval of Itvisma™ (onasemnogene abeparvovec-brve) by Novartis for adults and children 2 years of age and older living with SMA and all types of SMA. https://mma.prnewswire.com/media/2833006/Cure_SMA_Logo.jpg This newly approved one-time gene therapy delivers a functional SMN1 […]